Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 16, 2024 (filed on Mar 19, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:StockOptions (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,767Price:--
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,334Price:--
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13,425Price:$12.78
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7,101Price:$12.78
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,767Price:$9.41
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,334Price:$11.12
-
Feb 16, 2024 (filed on Feb 20, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-6,667Price:--
-
Feb 16, 2024 (filed on Feb 20, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,378Price:$12.41
-
Feb 16, 2024 (filed on Feb 20, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:6,667Price:--
Filings by filing date
-
Mar 16, 2024 (filed on Mar 19, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:StockOptions (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,767Price:--
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,334Price:--
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13,425Price:$12.78
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7,101Price:$12.78
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,767Price:$9.41
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Burgess JustinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,334Price:$11.12
-
Feb 15, 2024 (filed on Feb 20, 2024)Insider Name:Novack David FOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:67,860Price:--
-
Feb 15, 2024 (filed on Feb 20, 2024)Insider Name:Novack David FOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:95,000Price:--
-
Feb 15, 2024 (filed on Feb 20, 2024)Insider Name:Novack David FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,207Price:$9.45
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2100 Powell Street, Suite 720 EMERYVILLE CA 94608 |
Tel: | N/A |
Website: | https://www.dynavax.com |
IR: | See website |
Key People | ||
David F. Novack President, Chief Operating Officer | Ryan Spencer Chief Executive Officer, Director | Kelly MacDonald Chief Financial Officer, Senior Vice President | Robert Janssen Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs |
Business Overview |
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older. |
Financial Overview |
For the fiscal year ended 31 December 2023, Dynavax Technologies Corp revenues decreased 68% to $232.3M. Net loss applicable to common stockholders totaled $6.4M vs. income of $292.9M. Revenues reflect CpG 1018 segment decrease from $587.7M to $0K, Non-US segment decrease of 100% to $1.3M. Net loss reflects Compensation and related personnel costs increase of 21% to $63.9M (expense). |
Employees: | 408 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,101M as of Dec 31, 2023 |
Annual revenue (TTM): | $232.28M as of Dec 31, 2023 |
EBITDA (TTM): | -$29.71M as of Dec 31, 2023 |
Net annual income (TTM): | -$6.39M as of Dec 31, 2023 |
Free cash flow (TTM): | $96.46M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 130,614,772 as of Feb 20, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |